Drugs /

inotuzumab ozogamicin

Back to Drugs List
Associated Genetic Biomarkers

Overview

Generic Name(s):
inotuzumab ozogamicin
NCI Definition [1]:
A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.

Clinical Trials

View Clinical Trials for inotuzumab ozogamicin

Inotuzumab ozogamicin has been investigated in 23 clinical trials, of which 22 are open and 1 is closed. Of the trials investigating inotuzumab ozogamicin, 4 are phase 1 (4 open), 5 are phase 1/phase 2 (5 open), 10 are phase 2 (9 open), 3 are phase 3 (3 open), and 1 is phase 4 (1 open).

CD22 Expression, BCR-ABL1 Fusion, and t(9;22)(q34;q11) are the most frequent biomarker inclusion criteria for inotuzumab ozogamicin clinical trials.

B-cell acute lymphoblastic leukemia, acute lymphoblastic leukemia, and B-cell lymphoblastic lymphoma are the most common diseases being investigated in inotuzumab ozogamicin clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Inotuzumab Ozogamicin
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Inotuzumab Ozogamicin
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating inotuzumab ozogamicin and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
cmc-544, inotuzumab ozogamicin, way-207294, inotuzumab ozogamicin, way 207294, cmc544
Drug Categories [2]:
Immunotherapies
Drug Target(s) [2]:
CD22
NCIT ID [1]:
C71542

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.